Status:
COMPLETED
A Study to Determine the Effect and Safety of an Oral Janus Kinase 2 (JAK2)-Inhibitor (Ruxolitinib; INBC018424) in Patients With Multiple Myeloma
Lead Sponsor:
Incyte Corporation
Conditions:
Multiple Myeloma
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this study was to determine clinical efficacy and safety of ruxolitinib (INCB018424), a small molecule Janus kinase 2 (JAK2)-inhibitor, in patients with refractory or relapsed multiple ...
Detailed Description
The protocol was originally designed as a Simon two stage but after it was determined that the initial 13 patients enrolled did not meet the definition of a 'responder' according to the International ...
Eligibility Criteria
Inclusion
- Confirmed diagnosis of multiple myeloma with evidence of measurable disease.
- Relapsed or refractory disease with at least one line of prior therapy.
- Adequate bone marrow reserve.
Exclusion
- Received anti-cancer medications or investigational therapy in the past 28 days.
- Intracranial disease or epidural disease.
Key Trial Info
Start Date :
March 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2010
Estimated Enrollment :
13 Patients enrolled
Trial Details
Trial ID
NCT00639002
Start Date
March 1 2008
End Date
July 1 2010
Last Update
February 13 2018
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Highland, California, United States, 92346
2
Boynton Beach, Florida, United States, 33435
3
New York, New York, United States, 10011